← Eichor
Study identifier: NCT05841628 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Tolerability of 532 nm Laser Treatment of Port Wine Stains

Condition: Port-Wine Stain  ·  Sponsor: Massachusetts General Hospital

PhaseNA
Planned participants15
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

The goal of this study is to learn about treatment of port wine birthmarks treated with an FDA-approved 532 nm laser. The main questions it aims to answer are: * How well are the treatments tolerated? * Are there differences in tolerability of the treatment when a single high fluence laser pulse is used (the standard treatment) versus using multiple low fluence pulses? * Are there differences in results when using a single high fluence pulse versus multiple low fluence pulses? type of study: Clinical Trial Participants will undergo 3 monthly laser treatments with the 532 nm DermaV laser. Part of their birthmark will be treated with the standard single-pulse high fluence approach, and other parts will be treated with the multiple-pulse low fluence approach.

This description comes directly from the study's public registry record.

Talk to the study team

Cemre Turk, MD  ·  6175133337  ·  cturk@mgh.harvard.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Wellman Center for Photomedicine, Harvard Medical SchoolBoston, Massachusetts, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05841628